BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968-1976. [PMID: 20083659 DOI: 10.4049/jimmunol.0903296] [Cited by in Crossref: 242] [Cited by in F6Publishing: 196] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Nnane IP, Xu Z, Zhou H, Davis HM. Non-Clinical Pharmacokinetics, Prediction of Human Pharmacokinetics and First-in-Human Dose Selection for CNTO 5825, an Anti-Interleukin-13 Monoclonal Antibody. Basic Clin Pharmacol Toxicol 2015;117:219-25. [PMID: 25683750 DOI: 10.1111/bcpt.12391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
2 Feldmann S, Grimm I, Stöhr D, Antonini C, Lischka P, Sinzger C, Stegmann C. Targeted mutagenesis on PDGFRα-Fc identifies amino acid modifications that allow efficient inhibition of HCMV infection while abolishing PDGF sequestration. PLoS Pathog 2021;17:e1009471. [PMID: 33780515 DOI: 10.1371/journal.ppat.1009471] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists. Cytokine 2018;101:56-63. [PMID: 27567553 DOI: 10.1016/j.cyto.2016.08.014] [Cited by in Crossref: 94] [Cited by in F6Publishing: 71] [Article Influence: 18.8] [Reference Citation Analysis]
4 Fan Y, Neubert H. Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS. Anal Chem 2016;88:4239-47. [DOI: 10.1021/acs.analchem.5b03900] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 5.4] [Reference Citation Analysis]
5 Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med 2015;7:275ra21. [PMID: 25696000 DOI: 10.1126/scitranslmed.aaa1957] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
6 Yu HK, Lee HJ, Ahn JH, Lim IH, Moon JH, Yoon Y, Yi LS, Kim SJ, Kim JS. Immunoglobulin Fc domain fusion to apolipoprotein(a) kringle V significantly prolongs plasma half-life without affecting its anti-angiogenic activity. Protein Eng Des Sel 2013;26:425-32. [PMID: 23571426 DOI: 10.1093/protein/gzt015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
7 Okbazghi SZ, More AS, White DR, Duan S, Shah IS, Joshi SB, Middaugh CR, Volkin DB, Tolbert TJ. Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis. J Pharm Sci 2016;105:559-74. [PMID: 26869419 DOI: 10.1016/j.xphs.2015.11.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
8 Muzammil S, Mabus JR, Cooper PR, Brezski RJ, Bement CB, Perkinson R, Huebert ND, Thompson S, Levine D, Kliwinski C, Bradley D, Hornby PJ. FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric-coated capsules in cynomolgus macaques. Pharmacol Res Perspect 2016;4:e00218. [PMID: 27433338 DOI: 10.1002/prp2.218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
9 Kontos S, Hubbell JA. Drug development: longer-lived proteins. Chem Soc Rev 2012;41:2686-95. [PMID: 22310725 DOI: 10.1039/c2cs15289d] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
10 Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. Shortened engineered human antibody CH2 domains: increased stability and binding to the human neonatal Fc receptor. J Biol Chem 2011;286:27288-93. [PMID: 21669873 DOI: 10.1074/jbc.M111.254219] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
11 Datta-Mannan A, Lu J, Witcher DR, Leung D, Tang Y, Wroblewski VJ. The interplay of non-specific binding, target-mediated clearance and FcRn interactions on the pharmacokinetics of humanized antibodies. MAbs 2015;7:1084-93. [PMID: 26337808 DOI: 10.1080/19420862.2015.1075109] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
12 Ward ES, Devanaboyina SC, Ober RJ. Targeting FcRn for the modulation of antibody dynamics. Mol Immunol 2015;67:131-41. [PMID: 25766596 DOI: 10.1016/j.molimm.2015.02.007] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 9.0] [Reference Citation Analysis]
13 Napolitano M, Ruggiero A, Fontanella G, Fabbrocini G, Patruno C. New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding. Dermatol Ther 2021;34:e14475. [PMID: 33128337 DOI: 10.1111/dth.14475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Kelly RL, Yu Y, Sun T, Caffry I, Lynaugh H, Brown M, Jain T, Xu Y, Wittrup KD. Target-independent variable region mediated effects on antibody clearance can be FcRn independent. MAbs 2016;8:1269-75. [PMID: 27610650 DOI: 10.1080/19420862.2016.1208330] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
15 Tada M, Tatematsu K, Ishii-Watabe A, Harazono A, Takakura D, Hashii N, Sezutsu H, Kawasaki N. Characterization of anti-CD20 monoclonal antibody produced by transgenic silkworms (Bombyx mori). MAbs 2015;7:1138-50. [PMID: 26261057 DOI: 10.1080/19420862.2015.1078054] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
16 Booth BJ, Ramakrishnan B, Narayan K, Wollacott AM, Babcock GJ, Shriver Z, Viswanathan K. Extending human IgG half-life using structure-guided design. MAbs 2018;10:1098-110. [PMID: 29947573 DOI: 10.1080/19420862.2018.1490119] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
17 Goulet DR, Watson MJ, Tam SH, Zwolak A, Chiu ML, Atkins WM, Nath A. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance. Drug Metab Dispos 2018;46:1900-7. [PMID: 30232177 DOI: 10.1124/dmd.118.081893] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Datta-mannan A, Chow C, Dickinson C, Driver D, Lu J, Witcher DR, Wroblewski VJ. FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4 Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys. Drug Metab Dispos 2012;40:1545-55. [DOI: 10.1124/dmd.112.045864] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
19 Lee JU, Shin W, Son JY, Yoo KY, Heo YS. Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases. Int J Mol Sci 2017;18:E228. [PMID: 28124979 DOI: 10.3390/ijms18010228] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
20 Bae S, Sim T, Lim C, Kim D, Lee J, Park Y, Jung S, Choi I, Kwon S, Oh KT. HM10660A, a long-acting hIFN-α-2b, is a potent candidate for the treatment of hepatitis C through an enhanced biological half-life. Int J Pharm 2017;534:89-96. [PMID: 28982547 DOI: 10.1016/j.ijpharm.2017.09.074] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Hirasawa S, Kitahara Y, Okamatsu Y, Fujii T, Nakayama A, Ueno S, Ijichi C, Futaki F, Nakata K, Taki M. Facile and Efficient Chemoenzymatic Semisynthesis of Fc-Fusion Compounds for Half-Life Extension of Pharmaceutical Components. Bioconjug Chem 2019;30:2323-31. [PMID: 31038930 DOI: 10.1021/acs.bioconjchem.9b00235] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hanke N, Kunz C, Thiemann M, Fricke H, Lehr T. Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients. Pharmaceutics 2019;11:E152. [PMID: 30939793 DOI: 10.3390/pharmaceutics11040152] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
23 Sockolosky JT, Szoka FC. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 2015;91:109-24. [PMID: 25703189 DOI: 10.1016/j.addr.2015.02.005] [Cited by in Crossref: 106] [Cited by in F6Publishing: 87] [Article Influence: 17.7] [Reference Citation Analysis]
24 Geuijen KPM, Oppers-Tiemissen C, Egging DF, Simons PJ, Boon L, Schasfoort RBM, Eppink MHM. Rapid screening of IgG quality attributes - effects on Fc receptor binding. FEBS Open Bio 2017;7:1557-74. [PMID: 28979843 DOI: 10.1002/2211-5463.12283] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
25 Rossi EA, Chang CH, Cardillo TM, Goldenberg DM. Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo properties. Bioconjug Chem 2013;24:63-71. [PMID: 23116517 DOI: 10.1021/bc300488f] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
26 Mathur A, Arora T, Liu L, Crouse-Zeineddini J, Mukku V. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics. J Immunol Methods 2013;390:81-91. [PMID: 23384837 DOI: 10.1016/j.jim.2013.01.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
27 Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, Del Carmen Ordóñez M, Navarro-Sarabia F, Moreira V, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Cañete JD, de la Serna AR, Magallares B, Narváez J, Gómez-Reino JJ, Gonzalez A. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics 2015;16:333-45. [PMID: 25823782 DOI: 10.2217/pgs.14.175] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
28 Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Müller D, Kontermann RE. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 2010;23:827-34. [PMID: 20817756 DOI: 10.1093/protein/gzq058] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
29 Hall MP, Gegg C, Walker K, Spahr C, Ortiz R, Patel V, Yu S, Zhang L, Lu H, DeSilva B, Lee JW. Ligand-binding mass spectrometry to study biotransformation of fusion protein drugs and guide immunoassay development: strategic approach and application to peptibodies targeting the thrombopoietin receptor. AAPS J 2010;12:576-85. [PMID: 20625864 DOI: 10.1208/s12248-010-9218-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
30 Wang X, McKay P, Yee LT, Dutina G, Hass PE, Nijem I, Allison D, Cowan KJ, Lin K, Quarmby V, Yang J. Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data. MAbs 2017;9:319-32. [PMID: 28001487 DOI: 10.1080/19420862.2016.1261774] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
31 Kim SJ, Kwak H, Cho SY, Sohn YB, Park SW, Huh R, Kim J, Ko A, Jin D. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein. Mol Pharmaceutics 2015;12:3759-65. [DOI: 10.1021/acs.molpharmaceut.5b00550] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
32 O'Shannessy DJ, Bendas K, Schweizer C, Wang W, Albone E, Somers EB, Weil S, Meredith RK, Wustner J, Grasso L, Landers M, Nicolaides NC. Correlation of FCGRT genomic structure with serum immunoglobulin, albumin and farletuzumab pharmacokinetics in patients with first relapsed ovarian cancer. Genomics 2017;109:251-7. [PMID: 28450240 DOI: 10.1016/j.ygeno.2017.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
33 Pennington LF, Gasser P, Brigger D, Guntern P, Eggel A, Jardetzky TS. Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions. J Allergy Clin Immunol 2021:S0091-6749(21)00730-2. [PMID: 33991582 DOI: 10.1016/j.jaci.2021.03.050] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Malik PRV, Hamadeh A, Phipps C, Edginton AN. Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability. J Pharmacokinet Pharmacodyn 2017;44:277-90. [PMID: 28260166 DOI: 10.1007/s10928-017-9515-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
35 Basu S, Lien YTK, Vozmediano V, Schlender JF, Eissing T, Schmidt S, Niederalt C. Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim. Front Pharmacol 2020;11:868. [PMID: 32595502 DOI: 10.3389/fphar.2020.00868] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
36 Soleimanpour S, Hassannia T, Motiee M, Amini AA, Rezaee SA. Fcγ1 fragment of IgG1 as a powerful affinity tag in recombinant Fc-fusion proteins: immunological, biochemical and therapeutic properties. Crit Rev Biotechnol 2017;37:371-92. [PMID: 27049690 DOI: 10.3109/07388551.2016.1163323] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
37 AlRabiah H, Hamidaddin MA, Darwish IA. Automated flow fluorescent noncompetitive immunoassay for measurement of human plasma levels of monoclonal antibodies used for immunotherapy of cancers with KinExA™ 3200 biosensor. Talanta 2019;192:331-8. [PMID: 30348399 DOI: 10.1016/j.talanta.2018.09.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Gerosa M, Schioppo T, Meroni PL. Challenges and treatment options for rheumatoid arthritis during pregnancy. Expert Opinion on Pharmacotherapy 2016;17:1539-47. [DOI: 10.1080/14656566.2016.1197204] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
39 Sharma UR, Nediyedath Rathnakaran A, Raj BPP, Padinjakkara G, Das A, Vada S, Mudagal MP. The positive effect of pregnancy in rheumatoid arthritis and the use of medications for the management of rheumatoid arthritis during pregnancy. Inflammopharmacology 2021;29:987-1000. [PMID: 33844107 DOI: 10.1007/s10787-021-00808-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics. MAbs 2015;7:483-93. [PMID: 25695748 DOI: 10.1080/19420862.2015.1016696] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 13.4] [Reference Citation Analysis]
41 Souders CA, Nelson SC, Wang Y, Crowley AR, Klempner MS, Thomas W Jr. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. MAbs 2015;7:912-21. [PMID: 26018774 DOI: 10.1080/19420862.2015.1054585] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
42 Yu M, Benjamin MM, Srinivasan S, Morin EE, Shishatskaya EI, Schwendeman SP, Schwendeman A. Battle of GLP-1 delivery technologies. Advanced Drug Delivery Reviews 2018;130:113-30. [DOI: 10.1016/j.addr.2018.07.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 13.3] [Reference Citation Analysis]
43 Wang CP, Young G, Thornburg CD. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opin Drug Saf 2021;20:387-96. [PMID: 33612049 DOI: 10.1080/14740338.2021.1893303] [Reference Citation Analysis]
44 Fuhrmann S, Kloft C, Huisinga W. Impact of altered endogenous IgG on unspecific mAb clearance. J Pharmacokinet Pharmacodyn 2017;44:351-74. [PMID: 28439684 DOI: 10.1007/s10928-017-9524-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Nixon AE, Chen J, Sexton DJ, Muruganandam A, Bitonti AJ, Dumont J, Viswanathan M, Martik D, Wassaf D, Mezo A, Wood CR, Biedenkapp JC, TenHoor C. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol 2015;6:176. [PMID: 25954273 DOI: 10.3389/fimmu.2015.00176] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
46 Nath N, Godat B, Flemming R, Urh M. Deciphering the Interaction between Neonatal Fc Receptor and Antibodies Using a Homogeneous Bioluminescent Immunoassay. J Immunol 2021;207:1211-21. [PMID: 34312257 DOI: 10.4049/jimmunol.2100181] [Reference Citation Analysis]
47 van der Zwan M, Baan CC, van Gelder T, Hesselink DA. Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation. Clin Pharmacokinet 2018;57:191-207. [PMID: 28669130 DOI: 10.1007/s40262-017-0573-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 17.0] [Reference Citation Analysis]
48 Varkhede N, Bommana R, Schöneich C, Forrest ML. Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration. J Pharm Sci 2020;109:191-205. [PMID: 31408633 DOI: 10.1016/j.xphs.2019.08.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
49 Piche-Nicholas NM, Avery LB, King AC, Kavosi M, Wang M, O'Hara DM, Tchistiakova L, Katragadda M. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics. MAbs 2018;10:81-94. [PMID: 28991504 DOI: 10.1080/19420862.2017.1389355] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
50 Förger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Review of Clinical Immunology 2016;12:937-44. [DOI: 10.1080/1744666x.2016.1184973] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 3.6] [Reference Citation Analysis]
51 Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol 2017;10:661-9. [PMID: 28326845 DOI: 10.1080/17512433.2017.1305268] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
52 Tiwari PB, Üren A, He J, Darici Y, Wang X. Note: Model identification and analysis of bivalent analyte surface plasmon resonance data. Rev Sci Instrum 2015;86:106107. [PMID: 26521004 DOI: 10.1063/1.4933318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
53 Buchanan A, Revell JD. Novel Therapeutic Proteins and Peptides. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies. Elsevier; 2015. pp. 171-97. [DOI: 10.1016/b978-0-12-416603-5.00008-0] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
54 Ishino T, Wang M, Mosyak L, Tam A, Duan W, Svenson K, Joyce A, O'Hara DM, Lin L, Somers WS, Kriz R. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem 2013;288:16529-37. [PMID: 23615911 DOI: 10.1074/jbc.M113.457689] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
55 Liefferinckx C, Verstockt B, Gils A, Tops S, Van Moerkercke W, Vermeire S, Franchimont D. Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases. United European Gastroenterol J 2019;7:750-8. [PMID: 31316779 DOI: 10.1177/2050640619841538] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Majumdar R, Esfandiary R, Bishop SM, Samra HS, Middaugh CR, Volkin DB, Weis DD. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. MAbs 2015;7:84-95. [PMID: 25524268 DOI: 10.4161/19420862.2014.985494] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
57 Kiyoshi M, Tatematsu KI, Tada M, Sezutsu H, Shibata H, Ishii-Watabe A. Structural insight and stability of TNFR-Fc fusion protein (Etanercept) produced by using transgenic silkworms. J Biochem 2021;169:25-33. [PMID: 32766842 DOI: 10.1093/jb/mvaa092] [Reference Citation Analysis]
58 Billiet T, Dreesen E, Cleynen I, Wollants WJ, Ferrante M, Van Assche G, Gils A, Vermeire S. A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease. Am J Gastroenterol 2016;111:1438-45. [PMID: 27481307 DOI: 10.1038/ajg.2016.306] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
59 Shiga Y, Murata D, Sugimoto A, Oshima Y, Tada M, Ishii-watabe A, Imai K, Tomii K, Takeuchi T, Kagaya S, Sato A. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin. Mol Pharmaceutics 2017;14:3025-35. [DOI: 10.1021/acs.molpharmaceut.7b00221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
60 Bhargava R, Lehoux S, Maeda K, Tsokos MG, Krishfield S, Ellezian L, Pollak M, Stillman IE, Cummings RD, Tsokos GC. Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. JCI Insight 2021;6:147789. [PMID: 33784256 DOI: 10.1172/jci.insight.147789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Li L, Gardner I, Dostalek M, Jamei M. Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model. AAPS J 2014;16:1097-109. [PMID: 25004823 DOI: 10.1208/s12248-014-9640-5] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
62 Alvarez HM, So O, Hsieh S, Shinsky-bjorde N, Ma H, Song Y, Pang Y, Marian M, Escandón E. Effects of PEGylation and Immune Complex Formation on the Pharmacokinetics and Biodistribution of Recombinant Interleukin 10 in Mice. Drug Metab Dispos 2012;40:360-73. [DOI: 10.1124/dmd.111.042531] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
63 Jensen PF, Larraillet V, Schlothauer T, Kettenberger H, Hilger M, Rand KD. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry. Mol Cell Proteomics 2015;14:148-61. [PMID: 25378534 DOI: 10.1074/mcp.M114.042044] [Cited by in Crossref: 66] [Cited by in F6Publishing: 25] [Article Influence: 9.4] [Reference Citation Analysis]
64 Gómez Román VR, Murray JC, Weiner LM. Antibody-Dependent Cellular Cytotoxicity (ADCC). Antibody Fc. Elsevier; 2014. pp. 1-27. [DOI: 10.1016/b978-0-12-394802-1.00001-7] [Cited by in Crossref: 9] [Article Influence: 1.3] [Reference Citation Analysis]
65 Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 2016;8:120-8. [PMID: 26514880 DOI: 10.1080/19420862.2015.1113360] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
66 Wang Q, Xie X, Su F, Wang J, Chen S, Wang Q, Jiang D, Wang Y, Zhang T, Liu C, Han M, Tao T, Wu Q, Xi N, Li Z, Song H, Fang Y. A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults. International Immunopharmacology 2019;75:105807. [DOI: 10.1016/j.intimp.2019.105807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
67 Fonseca MHG, Furtado GP, Bezerra MRL, Pontes LQ, Fernandes CFC. Boosting half-life and effector functions of therapeutic antibodies by Fc-engineering: An interaction-function review. International Journal of Biological Macromolecules 2018;119:306-11. [DOI: 10.1016/j.ijbiomac.2018.07.141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
68 Borrok MJ, Wu Y, Beyaz N, Yu XQ, Oganesyan V, Dall'Acqua WF, Tsui P. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling. J Biol Chem 2015;290:4282-90. [PMID: 25538249 DOI: 10.1074/jbc.M114.603712] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 8.7] [Reference Citation Analysis]
69 Baldwin WM 3rd, Valujskikh A, Fairchild RL. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Am J Transplant 2019;19:1881-7. [PMID: 30903736 DOI: 10.1111/ajt.15366] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
70 Wei W, Rosenkrans ZT, Liu J, Huang G, Luo QY, Cai W. ImmunoPET: Concept, Design, and Applications. Chem Rev 2020;120:3787-851. [PMID: 32202104 DOI: 10.1021/acs.chemrev.9b00738] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 57.0] [Reference Citation Analysis]
71 Romanowska-Próchnicka K, Felis-Giemza A, Olesińska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D. The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021;22:2922. [PMID: 33805757 DOI: 10.3390/ijms22062922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
72 Hong J, Lee Y, Lee C, Eo S, Kim S, Lee N, Park J, Park S, Seo D, Jeong M, Lee Y, Yeon S, Bou-Assaf G, Sosic Z, Zhang W, Jaquez O. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab). MAbs 2017;9:364-82. [PMID: 28005456 DOI: 10.1080/19420862.2016.1264550] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 9.4] [Reference Citation Analysis]
73 Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung NK. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody. Cancer Immunol Res 2015;3:266-77. [PMID: 25542634 DOI: 10.1158/2326-6066.CIR-14-0230-T] [Cited by in Crossref: 45] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
74 Chowdary P, Fosbury E, Riddell A, Mathias M. ®) in hemophilia A]]>. JBM 2016;Volume 7:187-98. [DOI: 10.2147/jbm.s80814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 Gehlsen K, Gong R, Bramhill D, Wiersma D, Kirkpatrick S, Wang Y, Feng Y, Dimitrov DS. Pharmacokinetics of engineered human monomeric and dimeric CH2 domains. MAbs 2012;4:466-74. [PMID: 22699277 DOI: 10.4161/mabs.20652] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
76 Neuber T, Frese K, Jaehrling J, Jäger S, Daubert D, Felderer K, Linnemann M, Höhne A, Kaden S, Kölln J, Tiller T, Brocks B, Ostendorp R, Pabst S. Characterization and screening of IgG binding to the neonatal Fc receptor. MAbs 2014;6:928-42. [PMID: 24802048 DOI: 10.4161/mabs.28744] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
77 Kliwinski C, Cooper PR, Perkinson R, Mabus JR, Tam SH, Wilkinson TM, Giles-Komar J, Scallon B, Powers GD, Hornby PJ. Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice. Am J Physiol Gastrointest Liver Physiol 2013;304:G262-70. [PMID: 23220220 DOI: 10.1152/ajpgi.00340.2012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
78 Qi T, Cao Y. In Translation: FcRn across the Therapeutic Spectrum. Int J Mol Sci 2021;22:3048. [PMID: 33802650 DOI: 10.3390/ijms22063048] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
79 Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014;11:243-55. [PMID: 24393836 DOI: 10.1038/nrgastro.2013.253] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 15.4] [Reference Citation Analysis]
80 Guo R, Guo W, Cao L, Liu H, Liu J, Xu H, Huang W, Wang F, Hong Z. Fusion of an albumin-binding domain extends the half-life of immunotoxins. Int J Pharm 2016;511:538-49. [PMID: 27457423 DOI: 10.1016/j.ijpharm.2016.07.046] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
81 Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7-12. [PMID: 27123565 DOI: 10.1016/j.jri.2016.04.284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
82 Ternant D, Arnoult C, Pugnière M, Dhommée C, Drocourt D, Perouzel E, Passot C, Baroukh N, Mulleman D, Tiraby G, Watier H, Paintaud G, Gouilleux-Gruart V. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding. J Immunol 2016;196:607-13. [PMID: 26685205 DOI: 10.4049/jimmunol.1501780] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
83 Sand KM, Bern M, Nilsen J, Noordzij HT, Sandlie I, Andersen JT. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol 2014;5:682. [PMID: 25674083 DOI: 10.3389/fimmu.2014.00682] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 13.0] [Reference Citation Analysis]
84 Binder U, Skerra A. Current Strategies for Pharmacokinetic Optimization. In: Rosenberg A, Demeule B, editors. Biobetters. New York: Springer; 2015. pp. 269-311. [DOI: 10.1007/978-1-4939-2543-8_14] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Reynolds T, de Zafra C, Kim A, Gelzleichter TR. Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Elsevier; 2013. pp. 3-33. [DOI: 10.1016/b978-0-12-394810-6.00001-0] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
86 Chetty M, Li L, Rose R, Machavaram K, Jamei M, Rostami-Hodjegan A, Gardner I. Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model. Front Immunol 2014;5:670. [PMID: 25601866 DOI: 10.3389/fimmu.2014.00670] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
87 Owczarek W, Walecka I, Lesiak A, Czajkowski R, Reich A, Zerda I, Narbutt J. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol 2020;37:821-30. [PMID: 33603597 DOI: 10.5114/ada.2020.102089] [Reference Citation Analysis]
88 Robbie GJ, Criste R, Dall'acqua WF, Jensen K, Patel NK, Losonsky GA, Griffin MP. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013;57:6147-53. [PMID: 24080653 DOI: 10.1128/AAC.01285-13] [Cited by in Crossref: 169] [Cited by in F6Publishing: 84] [Article Influence: 21.1] [Reference Citation Analysis]
89 Malik PRV, Edginton AN. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients. CPT Pharmacometrics Syst Pharmacol 2019;8:835-44. [PMID: 31343836 DOI: 10.1002/psp4.12456] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
90 Fan YY, Avery LB, Wang M, O'Hara DM, Leung S, Neubert H. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice. MAbs 2016;8:848-53. [PMID: 27104806 DOI: 10.1080/19420862.2016.1178436] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
91 Stewart T, Koval WT, Molina SA, Bock SM, Lillard JW Jr, Ross RF, Desai TA, Koval M. Calibrated flux measurements reveal a nanostructure-stimulated transcytotic pathway. Exp Cell Res 2017;355:153-61. [PMID: 28390677 DOI: 10.1016/j.yexcr.2017.03.065] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
92 Suzuki T, Hashii N, Tada M, Ishii-Watabe A. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein. MAbs 2021;13:1923366. [PMID: 34030575 DOI: 10.1080/19420862.2021.1923366] [Reference Citation Analysis]
93 Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, Ruiz-Irastorza G, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810. [PMID: 26888948 DOI: 10.1136/annrheumdis-2015-208840] [Cited by in Crossref: 445] [Cited by in F6Publishing: 327] [Article Influence: 89.0] [Reference Citation Analysis]
94 Stavenhagen K, Gahoual R, Dominguez Vega E, Palmese A, Ederveen ALH, Cutillo F, Palinsky W, Bierau H, Wuhrer M. Site-specific N- and O-glycosylation analysis of atacicept. MAbs 2019;11:1053-63. [PMID: 31349756 DOI: 10.1080/19420862.2019.1630218] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
95 Iyengar ARS, Gupta S, Jawalekar S, Pande AH. Protein Chimerization: A New Frontier for Engineering Protein Therapeutics with Improved Pharmacokinetics. J Pharmacol Exp Ther 2019;370:703-14. [DOI: 10.1124/jpet.119.257063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Sharma S, Eckert D, Hyams JS, Mensing S, Thakkar RB, Robinson AM, Rosh JR, Ruemmele FM, Awni WM. Pharmacokinetics and exposure-efficacy relationship of adalimumab in pediatric patients with moderate to severe Crohn's disease: results from a randomized, multicenter, phase-3 study. Inflamm Bowel Dis. 2015;21:783-792. [PMID: 25723614 DOI: 10.1097/mib.0000000000000327] [Cited by in Crossref: 60] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
97 Carter PJ, Lazar GA. Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nat Rev Drug Discov 2018;17:197-223. [DOI: 10.1038/nrd.2017.227] [Cited by in Crossref: 322] [Cited by in F6Publishing: 254] [Article Influence: 80.5] [Reference Citation Analysis]
98 Gao X, Ji JA, Veeravalli K, Wang YJ, Zhang T, Mcgreevy W, Zheng K, Kelley RF, Laird MW, Liu J, Cromwell M. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation. J Pharm Sci 2015;104:368-77. [PMID: 25175600 DOI: 10.1002/jps.24136] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
99 Yamada T, Saito T, Hill Y, Shimizu Y, Tsukakoshi K, Mizuno H, Hayashi H, Ikebukuro K, Toyo'oka T, Todoroki K. High-Throughput Bioanalysis of Bevacizumab in Human Plasma Based on Enzyme-Linked Aptamer Assay Using Anti-Idiotype DNA Aptamer. Anal Chem 2019;91:3125-30. [PMID: 30667211 DOI: 10.1021/acs.analchem.8b05725] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
100 Datta-Mannan A, Wroblewski VJ. Application of FcRn binding assays to guide mAb development. Drug Metab Dispos 2014;42:1867-72. [PMID: 25024401 DOI: 10.1124/dmd.114.059089] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
101 Siriwattananon K, Manopwisedjaroen S, Kanjanasirirat P, Budi Purwono P, Rattanapisit K, Shanmugaraj B, Smith DR, Borwornpinyo S, Thitithanyanont A, Phoolcharoen W. Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2. Front Plant Sci 2020;11:604663. [PMID: 33584747 DOI: 10.3389/fpls.2020.604663] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
102 Ng CM, Loyet KM, Iyer S, Fielder PJ, Deng R. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. Eur J Pharm Sci 2014;51:51-8. [PMID: 23999033 DOI: 10.1016/j.ejps.2013.08.033] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
103 Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A, Waterman M, Ben-Horin S, Chowers Y. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther. 2014;40:620-628. [PMID: 25039584 DOI: 10.1111/apt.12869] [Cited by in Crossref: 126] [Cited by in F6Publishing: 112] [Article Influence: 18.0] [Reference Citation Analysis]
104 Pan X, Stader F, Abduljalil K, Gill KL, Johnson TN, Gardner I, Jamei M. Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. AAPS J 2020;22. [DOI: 10.1208/s12248-020-00460-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
105 Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, Khawli LA, Boswell CA. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. MAbs 2014;6:689-96. [PMID: 24572100 DOI: 10.4161/mabs.28254] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 7.7] [Reference Citation Analysis]
106 Shah DK. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn 2015;42:553-71. [PMID: 26373957 DOI: 10.1007/s10928-015-9447-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
107 Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect 2019;7:e00535. [PMID: 31859459 DOI: 10.1002/prp2.535] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
108 Urbanowicz RA, Lacek K, Lahm A, Bienkowska-Szewczyk K, Ball JK, Nicosia A, Cortese R, Pessi A. Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin. J Pept Sci 2015;21:743-9. [PMID: 26292842 DOI: 10.1002/psc.2802] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
109 Tada M, Ishii-Watabe A, Suzuki T, Kawasaki N. Development of a cell-based assay measuring the activation of FcγRIIa for the characterization of therapeutic monoclonal antibodies. PLoS One 2014;9:e95787. [PMID: 24752341 DOI: 10.1371/journal.pone.0095787] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
110 Czajkowsky DM, Hu J, Shao Z, Pleass RJ. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012;4:1015-28. [PMID: 22837174 DOI: 10.1002/emmm.201201379] [Cited by in Crossref: 251] [Cited by in F6Publishing: 191] [Article Influence: 27.9] [Reference Citation Analysis]
111 Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica 2014;44:1127-34. [PMID: 25030041 DOI: 10.3109/00498254.2014.941963] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
112 Goldenberg DM, Chang CH, Rossi EA, J W, McBride, Sharkey RM. Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2012;2:523-40. [PMID: 22737190 DOI: 10.7150/thno.3582] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 7.8] [Reference Citation Analysis]
113 Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015;21:182-197. [PMID: 25222660 DOI: 10.1097/mib.0000000000000202] [Cited by in Crossref: 100] [Cited by in F6Publishing: 32] [Article Influence: 16.7] [Reference Citation Analysis]
114 Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, Ionescu R. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011;48:860-6. [PMID: 21256596 DOI: 10.1016/j.molimm.2010.12.009] [Cited by in Crossref: 173] [Cited by in F6Publishing: 140] [Article Influence: 17.3] [Reference Citation Analysis]
115 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
116 Arnold KB, Chung AW. Prospects from systems serology research. Immunology 2018;153:279-89. [PMID: 29139548 DOI: 10.1111/imm.12861] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
117 Qin JJ, Wang W, Sarkar S, Zhang R. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release 2016;237:101-14. [PMID: 27394681 DOI: 10.1016/j.jconrel.2016.07.008] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
118 Strohl WR. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs 2015;29:215-39. [PMID: 26177629 DOI: 10.1007/s40259-015-0133-6] [Cited by in Crossref: 193] [Cited by in F6Publishing: 150] [Article Influence: 38.6] [Reference Citation Analysis]
119 Muñoz-Villegas P, Sanchez-Rios A, Quinonez-Alvarado MG, Olvera-Montaño O, Quintana-Hau JD, Baiza-Duran L. Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab. J Exp Pharmacol 2021;13:545-54. [PMID: 34113182 DOI: 10.2147/JEP.S308388] [Reference Citation Analysis]
120 Hardiansyah D, Ng CM. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling. MAbs 2018;10:1144-56. [PMID: 29969360 DOI: 10.1080/19420862.2018.1494479] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
121 Monnet C, Jorieux S, Souyris N, Zaki O, Jacquet A, Fournier N, Crozet F, de Romeuf C, Bouayadi K, Urbain R, Behrens CK, Mondon P, Fontayne A. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. MAbs 2014;6:422-36. [PMID: 24492301 DOI: 10.4161/mabs.27854] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 4.4] [Reference Citation Analysis]
122 Montes A, Perez-Pampin E, Navarro-Sarabia F, Moreira V, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Fernández-Nebro A, Ordóñez Mdel C, Narváez J, Cañete JD, Marquez A, Pascual-Salcedo D, Joven B, Carreira P, Moreno-Ramos MJ, Caliz R, Ferrer MA, Garcia-Portales R, Blanco FJ, Magro C, Raya E, Valor L, Alegre-Sancho JJ, Balsa A, Martin J, Plant D, Isaacs J, Morgan AW, Barton A, Wilson AG, Gómez-Reino JJ, Gonzalez A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS). Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. Arthritis Res Ther 2015;17:63. [PMID: 25885039 DOI: 10.1186/s13075-015-0571-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
123 Brülisauer L, Valentino G, Morinaga S, Cam K, Thostrup bukrinski J, Gauthier MA, Leroux J. Bio-reduction of Redox-Sensitive Albumin Conjugates in FcRn-Expressing Cells. Angew Chem Int Ed 2014;53:8392-6. [DOI: 10.1002/anie.201404238] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
124 Nnane IP, Han C, Jiao Q, Tam SH, Davis HM, Xu Z. Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. Basic Clin Pharmacol Toxicol 2017;121:13-21. [PMID: 28132416 DOI: 10.1111/bcpt.12761] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
125 Ng CM, Fielder PJ, Jin J, Deng R. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey. AAPS J 2016;18:948-59. [PMID: 27075465 DOI: 10.1208/s12248-016-9911-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
126 Yuan D, Rode F, Cao Y. A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies. AAPS J 2018;20:48. [PMID: 29541870 DOI: 10.1208/s12248-017-0183-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
127 Iwasaki K, Uno Y, Utoh M, Yamazaki H. Importance of cynomolgus monkeys in development of monoclonal antibody drugs. Drug Metab Pharmacokinet 2019;34:55-63. [PMID: 29655914 DOI: 10.1016/j.dmpk.2018.02.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
128 Arlotta KJ, Owen SC. Antibody and antibody derivatives as cancer therapeutics. WIREs Nanomed Nanobiotechnol 2019;11. [DOI: 10.1002/wnan.1556] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
129 Wang W, Lu P, Fang Y, Hamuro L, Pittman T, Carr B, Hochman J, Prueksaritanont T. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences. Drug Metab Dispos 2011;39:1469-77. [PMID: 21610128 DOI: 10.1124/dmd.111.039453] [Cited by in Crossref: 116] [Cited by in F6Publishing: 108] [Article Influence: 11.6] [Reference Citation Analysis]
130 Ostensen M, Förger F. Treatment with biologics of pregnant patients with rheumatic diseases. Curr Opin Rheumatol. 2011;23:293-298. [PMID: 21346578 DOI: 10.1097/bor.0b013e328344a732] [Cited by in Crossref: 37] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
131 Yuan D, Rode F, Cao Y. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. Eur J Pharm Sci 2019;138:105032. [PMID: 31394258 DOI: 10.1016/j.ejps.2019.105032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
132 Ferguson DC, Blanco JG. Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181. Pharm Res 2018;35:15. [PMID: 29302759 DOI: 10.1007/s11095-017-2294-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
133 Lo K, Leger O, Hock B, Crowe Jr. JE, Boraschi D. Antibody Engineering. Microbiol Spectr 2014;2. [DOI: 10.1128/microbiolspec.aid-0007-12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
134 Magistrelli G, Malinge P, Anceriz N, Desmurs M, Venet S, Calloud S, Daubeuf B, Kosco-Vilbois M, Fischer N. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies. J Immunol Methods 2012;375:20-9. [PMID: 21939661 DOI: 10.1016/j.jim.2011.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
135 Soleimanpour S, Mohammadi A, Ghazvini K, Jamehdar SA, Sadeghian H, Taghiabadi M, Rezaee SAR. Construction of Mycobacterium tuberculosis ESAT-6 fused to human Fcγ of IgG1: To target FcγR as a delivery system for enhancement of immunogenicity. Gene 2016;580:111-7. [PMID: 26778208 DOI: 10.1016/j.gene.2016.01.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
136 Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol 2011;22:868-76. [PMID: 21862310 DOI: 10.1016/j.copbio.2011.06.012] [Cited by in Crossref: 321] [Cited by in F6Publishing: 276] [Article Influence: 32.1] [Reference Citation Analysis]
137 Silacci M, Baenziger-Tobler N, Lembke W, Zha W, Batey S, Bertschinger J, Grabulovski D. Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency. J Biol Chem 2014;289:14392-8. [PMID: 24692552 DOI: 10.1074/jbc.M113.534578] [Cited by in Crossref: 28] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
138 Larena M, Prow NA, Hall RA, Petrovsky N, Lobigs M. JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8(+) T cells and pre-exposure neutralizing antibody. J Virol 2013;87:4395-402. [PMID: 23388724 DOI: 10.1128/JVI.03144-12] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 5.3] [Reference Citation Analysis]
139 Sampei Z, Haraya K, Tachibana T, Fukuzawa T, Shida-Kawazoe M, Gan SW, Shimizu Y, Ruike Y, Feng S, Kuramochi T, Muraoka M, Kitazawa T, Kawabe Y, Igawa T, Hattori K, Nezu J. Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody. PLoS One 2018;13:e0209509. [PMID: 30592762 DOI: 10.1371/journal.pone.0209509] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
140 Hasegawa H. Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology. Int J Cell Biol. 2013;2013:604867. [PMID: 23533417 DOI: 10.1155/2013/604867] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
141 Ying T, Chen W, Feng Y, Wang Y, Gong R, Dimitrov DS. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics. J Biol Chem 2013;288:25154-64. [PMID: 23867459 DOI: 10.1074/jbc.M113.484154] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
142 Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A 2015;112:5997-6002. [PMID: 25918417 DOI: 10.1073/pnas.1408766112] [Cited by in Crossref: 94] [Cited by in F6Publishing: 81] [Article Influence: 15.7] [Reference Citation Analysis]
143 Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011;3:76-99. [PMID: 21051951 DOI: 10.4161/mabs.3.1.13895] [Cited by in Crossref: 175] [Cited by in F6Publishing: 155] [Article Influence: 17.5] [Reference Citation Analysis]
144 Lim CN, Kantaridis C, Huyghe I, Gorman D, Berasi S, Sonnenberg GE. A Phase 1 first-in-human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF-06730512 in healthy participants. Pharmacol Res Perspect 2021;9:e00813. [PMID: 34369667 DOI: 10.1002/prp2.813] [Reference Citation Analysis]
145 Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin. J Immunol 2015;194:4595-603. [PMID: 25934922 DOI: 10.4049/jimmunol.1403014] [Cited by in Crossref: 136] [Cited by in F6Publishing: 113] [Article Influence: 22.7] [Reference Citation Analysis]
146 Lee J, Kang HA, Bae JS, Kim KD, Lee KH, Lim KJ, Choo MJ, Chang SJ. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses. MAbs 2018;10:547-71. [PMID: 29482416 DOI: 10.1080/19420862.2018.1440170] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
147 Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Wittrup KD, Xu Y. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs 2015;7:770-7. [PMID: 26047159 DOI: 10.1080/19420862.2015.1043503] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 9.8] [Reference Citation Analysis]
148 Abdiche YN, Yeung YA, Chaparro-Riggers J, Barman I, Strop P, Chin SM, Pham A, Bolton G, McDonough D, Lindquist K, Pons J, Rajpal A. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. MAbs 2015;7:331-43. [PMID: 25658443 DOI: 10.1080/19420862.2015.1008353] [Cited by in Crossref: 87] [Cited by in F6Publishing: 71] [Article Influence: 14.5] [Reference Citation Analysis]
149 Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A. Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide: NEUROMEDIN U-ALBUMIN CONJUGATE. J Pept Sci 2014;20:7-19. [DOI: 10.1002/psc.2582] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
150 Bruce VJ, Ta AN, Mcnaughton BR. Minimalist Antibodies and Mimetics: An Update and Recent Applications. ChemBioChem 2016;17:1892-9. [DOI: 10.1002/cbic.201600303] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
151 Poonia B, Kijak GH, Pauza CD. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One 2010;5:e15562. [PMID: 21187939 DOI: 10.1371/journal.pone.0015562] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
152 Yang B, Doshi S, Arkam K, Franklin J, Chow AT. Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective. Clin Pharmacokinet 2016;55:1045-58. [DOI: 10.1007/s40262-016-0382-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
153 Hager T, Spahr C, Xu J, Salimi-moosavi H, Hall M. Differential Enzyme-Linked Immunosorbent Assay and Ligand-Binding Mass Spectrometry for Analysis of Biotransformation of Protein Therapeutics: Application to Various FGF21 Modalities. Anal Chem 2013;85:2731-8. [DOI: 10.1021/ac303203y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
154 Hornby PJ, Cooper PR, Kliwinski C, Ragwan E, Mabus JR, Harman B, Thompson S, Kauffman AL, Yan Z, Tam SH, Dorai H, Powers GD, Giles-Komar J. Human and non-human primate intestinal FcRn expression and immunoglobulin G transcytosis. Pharm Res 2014;31:908-22. [PMID: 24072267 DOI: 10.1007/s11095-013-1212-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 5.4] [Reference Citation Analysis]
155 Gurbaxani B, Dostalek M, Gardner I. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Mol Immunol 2013;56:660-74. [PMID: 23917469 DOI: 10.1016/j.molimm.2013.05.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
156 Kelliny S, Bobrovskaya L, Zhou XF, Upton R. Pharmacokinetic Modelling of Human Recombinant Protein, p75ECD-Fc: A Novel Therapeutic Approach for Treatment of Alzheimer's Disease, in Serum and Tissue of Sprague Dawley Rats. Eur J Drug Metab Pharmacokinet 2021;46:235-48. [PMID: 33507523 DOI: 10.1007/s13318-020-00662-0] [Reference Citation Analysis]
157 Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655-672. [PMID: 25103255 DOI: 10.1038/nrd4363] [Cited by in Crossref: 868] [Cited by in F6Publishing: 685] [Article Influence: 124.0] [Reference Citation Analysis]
158 Matsumura T, Amatsu S, Misaki R, Yutani M, Du A, Kohda T, Fujiyama K, Ikuta K, Fujinaga Y. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B. Toxins (Basel) 2020;12:E302. [PMID: 32392791 DOI: 10.3390/toxins12050302] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
159 Feng Y, Gong R, Dimitrov DS. Design, expression and characterization of a soluble single-chain functional human neonatal Fc receptor. Protein Expr Purif 2011;79:66-71. [PMID: 21453773 DOI: 10.1016/j.pep.2011.03.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
160 Muslimov IA, Iacoangeli A, Eom T, Ruiz A, Lee M, Stephenson S, Ginzler EM, Tiedge H. Neuronal BC RNA Transport Impairments Caused by Systemic Lupus Erythematosus Autoantibodies. J Neurosci 2019;39:7759-77. [PMID: 31405929 DOI: 10.1523/JNEUROSCI.1657-18.2019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
161 Li L, Gardner I, Rose R, Jamei M. Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies. CPT Pharmacometrics Syst Pharmacol 2014;3:e96. [PMID: 24477089 DOI: 10.1038/psp.2013.73] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
162 Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. MAbs 2011;3:422-30. [PMID: 22048693 DOI: 10.4161/mabs.3.5.16983] [Cited by in Crossref: 158] [Cited by in F6Publishing: 143] [Article Influence: 15.8] [Reference Citation Analysis]
163 Khalili H, Godwin A, Choi J, Lever R, Khaw PT, Brocchini S. Fab-PEG-Fab as a Potential Antibody Mimetic. Bioconjugate Chem 2013;24:1870-82. [DOI: 10.1021/bc400246z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
164 Liu L, Gomathinayagam S, Hamuro L, Prueksaritanont T, Wang W, Stadheim TA, Hamilton SR. The Impact of Glycosylation on the Pharmacokinetics of a TNFR2:Fc Fusion Protein Expressed in Glycoengineered Pichia Pastoris. Pharm Res 2013;30:803-12. [DOI: 10.1007/s11095-012-0921-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
165 Kaufman PA, Wildiers H, Freyer G, Kemeny M, Gonçalves A, Jerusalem G, Stopeck A, Vrindavanam N, Dalenc F, Nanayakkara N, Wu B, Pickett CA. Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. Clin Breast Cancer 2019;19:47-57. [PMID: 30420181 DOI: 10.1016/j.clbc.2018.09.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
166 Lee JJ, Yang J, Lee C, Moon Y, Ahn S, Yang J. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®. Biologicals 2019;58:7-15. [DOI: 10.1016/j.biologicals.2018.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
167 Chen Y, Balthasar JP. Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn. AAPS J 2012;14:850-9. [PMID: 22956476 DOI: 10.1208/s12248-012-9395-9] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 8.2] [Reference Citation Analysis]
168 Maas BM, Cao Y. A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species. MAbs 2018;10:1322-31. [PMID: 30130450 DOI: 10.1080/19420862.2018.1506648] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
169 Datta-Mannan A. Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Drug Metab Dispos 2019;47:1100-10. [PMID: 31043438 DOI: 10.1124/dmd.119.086488] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
170 Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S. Placental Transfer of Fc-Containing Biopharmaceuticals across Species, an Industry Survey Analysis: PLACENTAL TRANSFER OF Fc BIOPHARMACEUTICALS. Birth Defects Res B 2013;98:459-85. [DOI: 10.1002/bdrb.21089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
171 Hall MP. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling. Drug Metab Dispos 2014;42:1873-80. [PMID: 24947971 DOI: 10.1124/dmd.114.058347] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 5.3] [Reference Citation Analysis]
172 Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF. Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration. MAbs 2012;4:243-55. [PMID: 22453096 DOI: 10.4161/mabs.4.2.19387] [Cited by in Crossref: 81] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
173 Todoroki K, Nakano T, Eda Y, Ohyama K, Hayashi H, Tsuji D, Min JZ, Inoue K, Iwamoto N, Kawakami A, Ueki Y, Itoh K, Toyo'oka T. Bioanalysis of bevacizumab and infliximab by high-temperature reversed-phase liquid chromatography with fluorescence detection after immunoaffinity magnetic purification. Anal Chim Acta 2016;916:112-9. [PMID: 27016445 DOI: 10.1016/j.aca.2016.02.029] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
174 Suzuki S, Annaka H, Konno S, Kumagai I, Asano R. Engineering the hinge region of human IgG1 Fc-fused bispecific antibodies to improve fragmentation resistance. Sci Rep 2018;8:17253. [PMID: 30467410 DOI: 10.1038/s41598-018-35489-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
175 Lagassé HAD, Hengel H, Golding B, Sauna ZE. Fc-Fusion Drugs Have FcγR/C1q Binding and Signaling Properties That May Affect Their Immunogenicity. AAPS J 2019;21. [DOI: 10.1208/s12248-019-0336-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
176 Bajardi-Taccioli A, Blum A, Xu C, Sosic Z, Bergelson S, Feschenko M. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Mol Immunol 2015;67:616-24. [PMID: 26254986 DOI: 10.1016/j.molimm.2015.06.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
177 Siriwattananon K, Manopwisedjaroen S, Shanmugaraj B, Rattanapisit K, Phumiamorn S, Sapsutthipas S, Trisiriwanich S, Prompetchara E, Ketloy C, Buranapraditkun S, Wijagkanalan W, Tharakhet K, Kaewpang P, Leetanasaksakul K, Kemthong T, Suttisan N, Malaivijitnond S, Ruxrungtham K, Thitithanyanont A, Phoolcharoen W. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates. Front Plant Sci 2021;12:682953. [PMID: 34054909 DOI: 10.3389/fpls.2021.682953] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
178 Karlsson R, Fridh V, Frostell Å. Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. J Pharm Anal 2018;8:138-46. [PMID: 29736301 DOI: 10.1016/j.jpha.2017.12.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
179 Liu L. Antibody Glycosylation and Its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc-Fusion Proteins. Journal of Pharmaceutical Sciences 2015;104:1866-84. [DOI: 10.1002/jps.24444] [Cited by in Crossref: 203] [Cited by in F6Publishing: 156] [Article Influence: 33.8] [Reference Citation Analysis]
180 Pawlowski JW, Bajardi-taccioli A, Houde D, Feschenko M, Carlage T, Kaltashov IA. Influence of glycan modification on IgG1 biochemical and biophysical properties. Journal of Pharmaceutical and Biomedical Analysis 2018;151:133-44. [DOI: 10.1016/j.jpba.2017.12.061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
181 Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32-38. [PMID: 24840548 DOI: 10.1111/nyas.12456] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
182 Matsushima S, Huang Y, Suzuki H, Nishino J, Lloyd P. Ethnic sensitivity assessment – pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. Expert Opinion on Drug Metabolism & Toxicology 2014;11:179-91. [DOI: 10.1517/17425255.2015.990438] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
183 Chung S, Nguyen V, Lin YL, Lafrance-Vanasse J, Scales SJ, Lin K, Deng R, Williams K, Sperinde G, Li JJ, Zheng K, Sukumaran S, Tesar D, Ernst JA, Fischer S, Lazar GA, Prabhu S, Song A. An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans. MAbs 2019;11:942-55. [PMID: 30982394 DOI: 10.1080/19420862.2019.1605270] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 9.5] [Reference Citation Analysis]
184 Kang W, Marasco WA, Tong HI, Byron MM, Wu C, Shi Y, Sun S, Sun Y, Lu Y. Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages. J Neuroinflammation 2014;11:195. [PMID: 25416164 DOI: 10.1186/s12974-014-0195-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
185 Chiu ML, Gilliland GL. Engineering antibody therapeutics. Curr Opin Struct Biol 2016;38:163-73. [PMID: 27525816 DOI: 10.1016/j.sbi.2016.07.012] [Cited by in Crossref: 86] [Cited by in F6Publishing: 62] [Article Influence: 17.2] [Reference Citation Analysis]
186 Nickles D, Chen HP, Li MM, Khankhanian P, Madireddy L, Caillier SJ, Santaniello A, Cree BA, Pelletier D, Hauser SL, Oksenberg JR, Baranzini SE. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet 2013;22:4194-205. [PMID: 23748426 DOI: 10.1093/hmg/ddt267] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.8] [Reference Citation Analysis]
187 Kontermann RE. Half-life extended biotherapeutics. Expert Opin Biol Ther 2016;16:903-15. [PMID: 26967759 DOI: 10.1517/14712598.2016.1165661] [Cited by in Crossref: 88] [Cited by in F6Publishing: 69] [Article Influence: 17.6] [Reference Citation Analysis]
188 Ishii-watabe A, Kuwabara T. Biosimilarity assessment of biosimilar therapeutic monoclonal antibodies. Drug Metabolism and Pharmacokinetics 2019;34:64-70. [DOI: 10.1016/j.dmpk.2018.11.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
189 Hou Y, Su H, Luo Z, Li M, Ma X, Ma N. Nutrient Optimization Reduces Phosphorylation and Hydroxylation Level on an Fc-Fusion Protein in a CHO Fed-Batch Process. Biotechnol J 2019;14:e1700706. [PMID: 29877623 DOI: 10.1002/biot.201700706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
190 Vinet É, De Moura C, Pineau CA, Abrahamowicz M, Curtis JR, Bernatsky S. Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study. Arthritis Rheumatol 2018;70:1565-71. [DOI: 10.1002/art.40536] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
191 Sheridan D, Yu ZX, Zhang Y, Patel R, Sun F, Lasaro MA, Bouchard K, Andrien B, Marozsan A, Wang Y, Tamburini P. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One 2018;13:e0195909. [PMID: 29649283 DOI: 10.1371/journal.pone.0195909] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 23.7] [Reference Citation Analysis]
192 Preijers T, Schütte LM, Kruip MJHA, Cnossen MH, Leebeek FWG, van Hest RM, Mathôt RAA. Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B. Therapeutic Drug Monitoring 2019;41:192-212. [DOI: 10.1097/ftd.0000000000000625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
193 Vugmeyster Y, Xu X, Theil FP, Khawli LA, Leach MW. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. World J Biol Chem 2012;3:73-92. [PMID: 22558487 DOI: 10.4331/wjbc.v3.i4.73] [Cited by in CrossRef: 150] [Cited by in F6Publishing: 120] [Article Influence: 16.7] [Reference Citation Analysis]
194 Levin D, Golding B, Strome SE, Sauna ZE. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015;33:27-34. [PMID: 25488117 DOI: 10.1016/j.tibtech.2014.11.001] [Cited by in Crossref: 89] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
195 Azanza J, Sádaba B, Gómez-guiu A. Monoclonal antibodies: Pharmacokinetics as a basis for new dosage regimens? J Oncol Pharm Pract 2015;21:370-6. [DOI: 10.1177/1078155214538085] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
196 Kimura K, Kobayashi D, Hatoyama S, Yamamoto M, Takayanagi R, Yamada Y. Effects of FCGRIIIa -158V/F polymorphism on antibody-dependent cellular cytotoxicity activity of adalimumab. APMIS 2017;125:1102-7. [DOI: 10.1111/apm.12754] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]